Pharmaxis has two respiratory products, Bronchitol® and Aridol®, approved in various world markets. Both products are Australian discoveries, developed by Pharmaxis and now manufactured for global markets at the Company’s purpose- built, high tech production and testing facility in Sydney Australia.

Bronchitol® for the treatment of cystic fibrosis was the subject of three large scale clinical trials and is approved and marketed in Europe, Russia, Australia and the United States.

More about Bronchitol 

Aridol® is a bronchial challenge test for the diagnosis and assessment of asthma. It is approved and marketed in the United States, Europe, Australia, Canada and Asia.

More about Aridol

For patients and healthcare professionals click here
For Pharmaxis trading terms and conditions - Australia (September 2016) click here